Centre Told To Decide On Cancer Drug At Low Price

KOCHI : The Kerala High Court on Tuesday directed the Union government to decide within one month whether it could intervene and make available a lifesaving medicine for breast cancer patients in the country at an affordable price.

“As per the available statistics, an alarming number of women succumb to breast cancer by reason of their inability to afford expensive treatment and medication. The right to life guaranteed under the Constitution, coupled with the State’s duty to improve public health, calls for emergent and effective action in the matter,” held the court.

The court was hearing a petition filed by a retired bank employee, diagnosed with HER2- Negative Metastatic Breast Cancer and is undergoing ‘targeted therapy’ treatment. The petitioner said she is receiving a monthly pension of ₹ 28,000 and the monthly cost of the medicines for her treatment comes to ₹63,480. One medicine, Ribociclib, alone costs ₹ 58,140 per month, she said.

Ribociclib is an imported medicine and if it’s manufactured in Inida the cost will come down substantially, the petitioner submitted.  Ribociclib presently enjoys a patent monopoly and its manufacturers are hence prevented from producing the medicine without the consent of the patent holder.

Section 92 of the Patents Act, 1970 provides for compulsory license and section 100 empowers the government to requisition lifesaving medicines in cases of extreme necessity, the petitioner said. Citing these, she had submitted a representation before various authorities requesting immediate action. She had received an acknowledgement from the Ministry of Women and Child Development that informed her that the representation is now before the Department for Promotion of Industry and Internal Trade (DPIIT).

  • Related Posts

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    BENGALURU: Sending a strong message against officials who have made it a habit to ignore the applications under Right to Information (RTI) Act, the Karnataka Information Commission has cracked the…

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    New Delhi: The number of drug samples declared as Not of Standard Quality (NSQ) by the drug regulators in the country has registered over two-fold growth during the 12 months of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Kerala Health Department Has Launched The MeHEALTH App

    Kerala Health Department Has Launched The MeHEALTH App

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains